Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Other Working Capital Changes (2016 - 2025)

Coherus Oncology (CHRS) has disclosed Other Working Capital Changes for 13 consecutive years, with -$62.0 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 1688.96% to -$62.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$64.4 million through Dec 2025, down 7790.45% year-over-year, with the annual reading at -$64.4 million for FY2025, 7790.45% down from the prior year.
  • Other Working Capital Changes hit -$62.0 million in Q4 2025 for Coherus Oncology, down from -$2.0 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $11.5 million in Q3 2024 to a low of -$62.0 million in Q4 2025.
  • Historically, Other Working Capital Changes has averaged -$4.0 million across 5 years, with a median of -$1.1 million in 2022.
  • Biggest five-year swings in Other Working Capital Changes: soared 3531.01% in 2024 and later plummeted 1688.96% in 2025.
  • Year by year, Other Working Capital Changes stood at -$2.3 million in 2021, then plummeted by 475.52% to -$13.2 million in 2022, then dropped by 22.85% to -$16.2 million in 2023, then skyrocketed by 78.64% to -$3.5 million in 2024, then tumbled by 1688.96% to -$62.0 million in 2025.
  • Business Quant data shows Other Working Capital Changes for CHRS at -$62.0 million in Q4 2025, -$2.0 million in Q3 2025, and -$2.2 million in Q2 2025.